|
Originally published In Press as doi:10.1194/jlr.M200480-JLR200 on April 1, 2003
Journal of Lipid Research, Vol. 44, 1167-1173, June 2003
Copyright © 2003 by Lipid Research, Inc.
Genetic analysis of a polymorphism in the human apoA-V gene
:
effect on plasma lipids
Bradley E. Aouizerat1,*, ,
Medha Kulkarni ,
David Heilbron ,
Donna Drown ,
Stephen Raskin ,
Clive R. Pullinger ,
Mary J. Malloy and
John P. Kane
* Department of Physiological Nursing, University of California San Francisco, San Francisco, CA 94143
Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA 94143
Department of Medicine, University of California San Francisco, San Francisco, CA 94143
1 To whom correspondence should be addressed. e-mail: bradley.aouizerat{at}nursing.ucsf.edu
Recent discovery and characterization of APOAV suggests a role in metabolism of triglyceride (TG)-rich lipoproteins. Previously, variation at the APOAV locus was shown to modestly influence plasma TGs in normolipidemic samples. The aims of this study were to assess the effects of a polymorphism in APOAV (T-1131C) in terms of its frequency among three dyslipidemic populations and a control population, differences of allele frequency across available ethnic groups, and associations with specific lipoprotein TG and cholesterol compartments. We found a striking elevation in the frequency of the rare allele in a Chinese population (P = 0.0002) compared with Hispanic and European populations. The rare allele of the polymorphism was associated with elevated plasma TG (P = 0.012), VLDL cholesterol (P = 0.0007), and VLDL TG (P = 0.012), LDL TG (P = 0.003), and HDL TG (P = 0.016). Linear regression models predict that possession of the rare allele elevates plasma TG by 21 mg/dl (P = 0.009) and VLDL cholesterol by 8 mg/dl (P = 0.0001), and reduces HDL cholesterol by 2 mg/dl (P = 0.017). The association of the polymorphism with altered lipoprotein profiles was observed in combined hyperlipidemia, hypoalphalipoproteinemia, and hyperalphalipoproteinemia, and in controls.
These findings indicate that APOAV is an important determinant of plasma TG and lipoprotein cholesterol, and is potentially a risk factor for cardiovascular disease.
Supplementary key words lipoprotein dyslipidemia ethnicity

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
P.-P. Laurila, J. Naukkarinen, K. Kristiansson, S. Ripatti, T. Kauttu, K. Silander, V. Salomaa, M. Perola, P. J. Karhunen, P. J. Barter, et al.
Genetic Association and Interaction Analysis of USF1 and APOA5 on Lipid Levels and Atherosclerosis
Arterioscler Thromb Vasc Biol,
February 1, 2010;
30(2):
346 - 352.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. R. Pullinger, B. E. Aouizerat, I. Movsesyan, V. Durlach, E. J. Sijbrands, K. Nakajima, A. Poon, G. M. Dallinga-Thie, H. Hattori, L. L. Green, et al.
An apolipoprotein A-V gene SNP is associated with marked hypertriglyceridemia among Asian-American patients
J. Lipid Res.,
August 1, 2008;
49(8):
1846 - 1854.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y Yamada, S Ichihara, K Kato, T Yoshida, K Yokoi, H Matsuo, S Watanabe, N Metoki, H Yoshida, K Satoh, et al.
Genetic risk for metabolic syndrome: examination of candidate gene polymorphisms related to lipid metabolism in Japanese people
J. Med. Genet.,
January 1, 2008;
45(1):
22 - 28.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Grallert, E.-M. Sedlmeier, C. Huth, M. Kolz, I. M. Heid, C. Meisinger, C. Herder, K. Strassburger, A. Gehringer, M. Haak, et al.
APOA5 variants and metabolic syndrome in Caucasians
J. Lipid Res.,
December 1, 2007;
48(12):
2614 - 2621.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Sundl, M. Guardiola, G. Khoschsorur, R. Sola, J. C. Vallve, G. Godas, L. Masana, M. Maritschnegg, A. Meinitzer, N. Cardinault, et al.
Increased concentrations of circulating vitamin E in carriers of the apolipoprotein A5 gene 1131T>C variant and associations with plasma lipids and lipid peroxidation
J. Lipid Res.,
November 1, 2007;
48(11):
2506 - 2513.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Qu, G. Perdomo, D. Su, F. M. D'Souza, N. S. Shachter, and H. H. Dong
Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice
J. Lipid Res.,
July 1, 2007;
48(7):
1476 - 1487.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Elosua, J. M. Ordovas, L. A. Cupples, C.-Q. Lai, S. Demissie, C. S. Fox, J. F. Polak, P. A. Wolf, R. B. D'Agostino Sr., and C. J. O'Donnell
Variants at the APOA5 locus, association with carotid atherosclerosis, and modification by obesity: the Framingham Study
J. Lipid Res.,
May 1, 2006;
47(5):
990 - 996.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Hodoglugil, S. Tanyolac, D. W. Williamson, Y. Huang, and R. W. Mahley
Apolipoprotein A-V: a potential modulator of plasma triglyceride levels in Turks
J. Lipid Res.,
January 1, 2006;
47(1):
144 - 153.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. E. Schultze, W. E. Alborn, R. K. Newton, and R. J. Konrad
Administration of a PPAR{alpha} agonist increases serum apolipoprotein A-V levels and the apolipoprotein A-V/apolipoprotein C-III ratio
J. Lipid Res.,
August 1, 2005;
46(8):
1591 - 1595.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-O. Olofsson
ApoA-V: The Regulation of a Regulator of Plasma Triglycerides
Arterioscler Thromb Vasc Biol,
June 1, 2005;
25(6):
1097 - 1099.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Nowak, A. Helleboid-Chapman, H. Jakel, G. Martin, D. Duran-Sandoval, B. Staels, E. M. Rubin, L. A. Pennacchio, M.-R. Taskinen, J. Fruchart-Najib, et al.
Insulin-Mediated Down-Regulation of Apolipoprotein A5 Gene Expression through the Phosphatidylinositol 3-Kinase Pathway: Role of Upstream Stimulatory Factor
Mol. Cell. Biol.,
February 15, 2005;
25(4):
1537 - 1548.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. J. O'Brien, W. E. Alborn, J. H. Sloan, M. Ulmer, A. Boodhoo, M. D. Knierman, A. E. Schultze, and R. J. Konrad
The Novel Apolipoprotein A5 Is Present in Human Serum, Is Associated with VLDL, HDL, and Chylomicrons, and Circulates at Very Low Concentrations Compared with Other Apolipoproteins
Clin. Chem.,
February 1, 2005;
51(2):
351 - 359.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-Q. Lai, S. Demissie, L. A. Cupples, Y. Zhu, X. Adiconis, L. D. Parnell, D. Corella, and J. M. Ordovas
Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study
J. Lipid Res.,
November 1, 2004;
45(11):
2096 - 2105.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. G. Schaap, P. C. N. Rensen, P. J. Voshol, C. Vrins, H. N. van der Vliet, R. A. F. M. Chamuleau, L. M. Havekes, A. K. Groen, and K. W. van Dijk
ApoAV Reduces Plasma Triglycerides by Inhibiting Very Low Density Lipoprotein-Triglyceride (VLDL-TG) Production and Stimulating Lipoprotein Lipase-mediated VLDL-TG Hydrolysis
J. Biol. Chem.,
July 2, 2004;
279(27):
27941 - 27947.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q.-f. Wang, X. Liu, J. O'Connell, Z. Peng, R. M. Krauss, D. L. Rainwater, J. L. VandeBerg, Edward. M. Rubin, J.-F. Cheng, and L. A. Pennacchio
Haplotypes in the APOA1-C3-A4-A5 gene cluster affect plasma lipids in both humans and baboons
Hum. Mol. Genet.,
May 15, 2004;
13(10):
1049 - 1056.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Mar, P. Pajukanta, H. Allayee, M. Groenendijk, G. Dallinga-Thie, R. M. Krauss, J. S. Sinsheimer, R. M. Cantor, T. W.A. de Bruin, and A. J. Lusis
Association of the APOLIPOPROTEIN A1/C3/A4/A5 Gene Cluster With Triglyceride Levels and LDL Particle Size in Familial Combined Hyperlipidemia
Circ. Res.,
April 16, 2004;
94(7):
993 - 999.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. J. Talmud, S. Martin, M.-R. Taskinen, M. H. Frick, M. S. Nieminen, Y. A. Kesaniemi, A. Pasternack, S. E. Humphries, and M. Syvanne
APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study
J. Lipid Res.,
April 1, 2004;
45(4):
750 - 756.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-Q. Lai, E-S. Tai, C. E. Tan, J. Cutter, S. K. Chew, Y.-P. Zhu, X. Adiconis, and J. M. Ordovas
The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore
J. Lipid Res.,
December 1, 2003;
44(12):
2365 - 2373.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|